The transdermal (percutaneous) drug delivery systems market is expected to register a healthy CAGR over the forecast period. The transdermal (percutaneous) drug delivery systems market held a market value of USD 5,400.2 million in 2017 and is projected to grow at a CAGR of 5.56% during the forecast period from 2020 to 2030. Transdermal drug delivery system (TDDS) delivers drugs through the skin to systemic circulation at a predetermined rate and maintain the effective concentrations clinically over an extended period. TDDS also called as patches are dosage forms that deliver a therapeutically effective amount of drug via the patients’ skin. Worldwide growing geriatric population along with rising in the prevalence of chronic diseases is the leading factor driving the market growth. In addition, rapid technological advancements in transdermal drug delivery systems and increasing adoption of third-generation delivery systems are expected to augment the market growth during the forecast period. The geriatric population is more prone to develop Q fever. The elderly population across the world is on the surge. The World Health Organization (WHO) reported that the worldwide population aged 60 years and above was 962.0 million in 2017, which is projected to increase to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100.
However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin's impermeability, and lack of adhesion of the transdermal system to different skin types are anticipated to hinder the market growth over the forecast period. Additionally, drugs that require high blood levels cannot be administered through TDDS as it is limited only to potent molecules, those requiring a daily dose of 10 mg or less, thereby affecting the market growth.
The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.
By product, the market has been segmented into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches. The transdermal semisolids segment is additionally divided into gels, ointments, and sprays. The transdermal patches segment spearheaded the market in 2017 due to its benefits offered such as improved bioavailability, reduced dosing frequency, lower adverse events, enhanced patient compliance (non-invasive nature), painless application, and drug input termination at any point by the removal of the patch.
On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.
Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.
The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transdermal (percutaneous) drug delivery systems market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European transdermal (percutaneous) drug delivery systems market has been segmented into Western Europe and Eastern Europe. The Western Europe transdermal (percutaneous) drug delivery systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The transdermal (percutaneous) drug delivery systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Transdermal (Percutaneous) Drug Delivery Systems Market Share (%), by Region, 2017
Source: White Papers, Company Presentations, Annual Reports
Geographically, in 2017, the Americas led the global transdermal (percutaneous) drug delivery systems market due to the presence of major market players (Pfizer Inc., and Johnson & Johnson Services, Inc.) and developed healthcare infrastructure, surging number of research activities related to transdermal drug delivery systems, and comparatively higher adoption of TDDS system in the US and Canada.
Europe would be the second leader in the transdermal (percutaneous) drug delivery systems market owing to phenomenal growth in the pharmaceutical industry coupled with the headquarters of Novartis International AG, Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Boehringer Ingelheim International GmbH, and Allergan plc.
Growing elderly population base coupled with the rising prevalence of chronic diseases such as cardiovascular diseases (CVDs) and chronic pain in India, China, and Japan are likely to support the profitable growth of the Asia-Pacific throughout the forecast period. For instance, the CADI (Coronary Artery Disease among Asian Indians) Research Foundation reported that hypertension is the most prevalent disease in India and the number of people suffering from hypertension in the country was 118.0 million in 2000, which is estimated to reach to 214.0 million by 2025.
The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa would register the modest market growth rate from 2018 to 2023. The increasingly gentrified populations in the Gulf Cooperation Council (GCC) countries and Sub-Saharan African countries, and the development of sophisticated universal healthcare systems in the Middle East are expected to assist in the market growth during next five years.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Technology, Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Endo Pharmaceuticals Inc., UCB S.A., Pfizer Inc., Allergan plc, Actelion Pharmaceuticals Ltd, Noven Pharmaceuticals, Inc.|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Transdermal drug delivery system (TDDS) delivers drugs into systemic circulation into the skin through the skin at a predetermined rate with minimal inter and intrapatient variation.
Transdermal drug delivery systems market was valued at USD 8100.2 million in 2030.
The global market is expected to exhibit a solid 5.56% CAGR over the forecast period.
The increasing prevalence of chronic diseases is the major driver for the market.
The Americas dominate the global transdermal drug delivery systems market, followed by Europe.
Leading players in the market include Mylan, Endo Pharmaceuticals, Pfizer, Allergan, and Noven Pharmaceuticals, among others.